A

Austin Institute for Clinical Research | Pflugerville, TX

Research site
(Unclaimed)
Location
1601 E Pflugerville Parkway, Suite 1101, Pflugerville, Texas, United States of America

Site insights

Top conditions

Top treatments

LY3009104
Baricitinib
Apremilast
JNJ-77242113
OnabotulinumtoxinA
AGN-151586
BOTOX
Glycopyrronium
CC-10004
Sebum

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 53 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-reco...

Enrolling
Alopecia Areata
Drug: Rezpegaldesleukin
Drug: Placebo

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the...

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo
Locations recently updated

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Enrolling
Masseter Muscle Prominence
Drug: Placebo
Drug: BOTOX

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This trial is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared...

Enrolling
Lower Eyelid Steatoblepharon
Drug: Placebo
Drug: POLAT-001

The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common wart...

Enrolling
Common Warts (Verruca Vulgaris)
Drug: Placebo
Drug: Candin, Intradermal Solution

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Invitation-only
Alopecia Areata
Drug: CTP-543

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Guselkumab
Drug: Placebo

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-Rhod...

Enrolling
Acne Vulgaris
Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and...

Enrolling
Plaque Psoriasis
Drug: TLL018 tablets

Trial sponsors

Allergan logo
Lilly logo
AbbVie logo
J
Amgen logo
D
B
J
Pfizer logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems